BeyondSpring Inc. reports developments tied to its clinical-stage oncology pipeline, led by Plinabulin, an immune-modulating cancer therapy studied in non-small cell lung cancer and other indications. Recurring updates cover DUBLIN-3 data analyses, Plinabulin combinations with docetaxel, checkpoint inhibitors and antibody-drug conjugates, and presentations at oncology and immuno-oncology medical meetings.
Company news also includes periodic financial results, annual-report announcements, capital and corporate updates, and disclosures related to BeyondSpring’s equity interest in SEED Therapeutics and molecular glue degrader programs. These updates connect the company’s research activity, clinical-development strategy and financing actions with its public-company reporting cycle.
BeyondSpring Inc. (NASDAQ: BYSI) has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the SEC, showcasing audited financial statements. The report can be accessed on the SEC's website and the company's site, offering hard copies to shareholders upon request.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.